Multiple endocrine neoplasia type 2 (MEN 2) is an inherited disease caused by germline mutations in the RET proto-oncogene. The most distinctive MEN 2 variants are MEN 2A, MEN 2B and familial medullary thyroid cancer (FMTC). The hallmark of these syndromes is the development of medullary thyroid carcinoma (MTC), which occurs in almost all patients with MEN 2 syndromes. Other endocrinopathies are variably expressed. Pheochromocytoma and hyperparathyroidism occur in patients with MEN 2A with a frequency of about 50% and 30%, respectively. In this paper we summarize the most relevant diagnostic methods to detect and monitor MTC, pheochromocytoma and hyperparathyroidism.
PasiniB., RossiR., AmbrosioM.R., ZatelliM.C., GulloM., GobboM., ColliniP., AielloA., PansiniG., TrasforiniG., Ciro degli UbertiE.: RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Surgery, 131: 373–381, 2002.
2.
HuangS.C., Torres-CruzJ., PackS.D., KochC.A., VortmeyerA.O., MannanP., LubenskyI.A., GagelR.F., ZhuangZ.: Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocrinol Metab, 88: 459–463, 2003.
3.
KleinI., EsikO., HomolyaV., SzeriF., VaradiA.: Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol, 170: 661–666, 2001.
4.
LemosM.C., CarrilhoF., RodriguesF.J., SantosP., CarvalheiroM., RuasM.A., RegateiroF.J.: Early onset of medullary thyroid carcinoma in kindred with multiple endocrine neoplasia type IIA associated with cutaneous lichen amyloidosis. Endocr Pract, 8: 19–22, 2002.
5.
SansoG.E., DomeneH.M., Garcia RudazM.C., PusiolE., de MondinoA.K., RoqueM., RingA., PerinettiH., EisnerB., IorcanskyS., BarontiniM.: Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children. Cancer, 94: 323–330, 2002.
6.
CohenM.S., PhayJ.E., AlbisonC., De BenedettiM.K., SkinnerM.A., LairmoreT.C., DohertyG.M., BalfeD.M., WellsS.A., MoleyJ.F.: Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg, 235: 648–655, 2002.
7.
BrandiM.L., GagelR.F., AngeliA., BilezikianJ.P., Beck-PeccozP., BordiC., Conte-DevolxB., FalchettiA., GheriR.G., LibroiaA., LipsC.J.M., LombardiG., MannelliM., PaciniF., PonderB.A.J., RaueF., SkogseinB., TamburranoG., ThakkerR.V., ThompsonN.W., TomassettiP., TonelliF., WellsS.A., MarxS.J.: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab, 86: 5658–5671, 2001.
8.
UwaifoG.I., RemaleyA.T., SteneM., ReynoldsJ.C., YenP.M., SniderR.H., BeckerK.L., SarlisN.J.: A case of spurious hypercalcitoninemia: a cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia. J Endocrinol Invest, 24: 361–369, 2001.
SawkaA.M., JaeschkeR., SinghR.J., YoungW.F.Jr.: A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab, 88: 553–558, 2003.
14.
KjaerA., PetersenC.L.: Primary diagnosis of multiple pheochromocytomas in the brother of a MEN-2 patient by simultaneous MIBG scintigraphy and low-dose computed tomography. Clin Nucl Med, 27: 868–870, 2002.
15.
KraimpsJ.L., DenizotA., CarnailleB., HenryJ.F., ProyeC., BacourtF., SarfatiE., DupondJ.L., MaesB., TravagliJ.P., BoneuA., RogerP., HoudentC., BarbierJ., ModiglianiE.: Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. World J Surg, 20: 808–812, 1996.
16.
MarxS.J., SimondsE.F., AgarwalS.K., BurnsA.L., WrinsteinL.S., CochranC., SkarulisM.C., SpiegelA.M., LibuttiS.K., AlexanderH.R.J., ChenC.C., ChangR., ChandrasekharappaS.C., CollinsF.S.: Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res, 17: 37–43, 2002.
17.
GoldesteinR.E., BillheimerD., MartinW.H., RichardsK.: SestaMIBI scanning invasive radioguided parathyroidectomy without intraoperative parathyroid hormone measurement. Ann Surg, 237: 722–731, 2003.
18.
SekiyamaK., AkakuraK., MikamiK., MizoguchiK., TobeT., NakanoK., NumataT., KonnoA.: Usefulness of diagnostic imaging in primary hyperparathyroidism. Int J Urol, 10: 7–11, 2003.
